Abstract:
A method of treating coronary vascular disease in a human including the administration of a serum cholesterol reducing effective amount of DHA-containing single cell oil to the human.
Abstract:
The present invention relates to processes for the production of arachidonic acid containing oils, which preferably are substantially free of eicosapentaneoic acid. The invention also relates to compositions containing oils having very high amounts of arachidonic acid in triglyceride form, and to uses of such oils. In a preferred embodiment, Mortierella alpina is cultivated using conditions which yield triglyceride oil having particularly high levels of arachidonic acid residues, biomass is harvested and the oil is extracted, recovered, and used as an additive for infant formula.
Abstract:
Combinatorial libraries of labeled biochemical compounds and methods for producing such combinatorial libraries comprising the steps of producing labeled individual units, combining at least two of the labeled individual units so as to produce a labeled biochemical compound, and repeating this process at least once so as to produce a combinatorial library of labeled biochemical compounds. Also, methods for determining the conformation of a biochemical compound which comprise producing a combinatorial library of labeled biochemical compounds, contacting the combinatorial library of labeled biochemial compounds with a target receptor molecule so that a selected labeled biochemical compound binds to the target receptor molecule, and determining the conformation of the selected labeled biochemical compound when bound to the receptor molecule.
Abstract:
A method of treating a neurological disorder comprises administering to a person affected from such a disorder a microbial oil comprising DHA, a microbial oil comprising ARA or a combination of DHA and ARA oils in an amount sufficient to elevate the levels of circulating DHA and/or ARA in the person's blood to at least normal levels.
Abstract:
Genetic fusions for use in genetic engineering of eukaryotic algae employ a promoter from a light harvesting protein fused to a protein of interest. The fusions can be introduced and selected using an antibiotic resistance determinant. One gene useful for such selection is the sh ble gene encoding a bleomycin binding protein.
Abstract:
A simplified, user-friendly method and apparatus for collecting and storing a human breath sample and for detecting and indicating whether the stored breath sample is a true alveolar sample. The invention includes in one embodiment thereof a preferably transparent container (1) and a breath delivery device (6) for directing a subject's breath into the container (1). A closure device (5) is provided for accomodating the insertion of the breath delivery device (6) into the container (1) and for substantially sealing the container (1). A detector (12) is provided for being positioned within the sealed container (1) for detecting and indicating to an observer whether the breath sample stored in the container (1) is a true alveolar sample.
Abstract:
A method of treating a neurological disorder comprises administering to a person affected from such a disorder a microbial oil comprising DHA, a microbial oil comprising ARA or a combination of DHA and ARA oils in an amount sufficient to elevate the levels of circulating DHA and/or ARA in the person's blood to at least normal levels.
Abstract:
Methods are provided for generating highly diverse mixtures of compounds which may be screened for biological activities. Once the activity is found, the component of the mixture which is responsible for the activity can be isolated by fractionation and assay for the biological activity. Polyhydroxylated organic monomers and oligomers are used as starting materials for generating the libraries.
Abstract:
A method for determining three-dimensional structural information of a protein involves producing the protein in a form substantially labeled with C or N or both or substantially labeled with N and C and partially labeled with H and subjecting the protein to nuclear magnetic resonance spectroscopic analysis. The isotopically labeled protein is produced by a method which involves producing a substantially labeled microbial protein hydrolysate, subjecting the protein hydrolysate to cation exchange chromatography to produce a partially purified labeled amino acid mixture, subjecting the partially purified labeled amino acid mixture to anion exchange chromatography to produce a purified labeled amino acid mixture and supplementing the purified labeled amino acid mixture with isotopically labeled cysteine and optionally with isotopically labeled glutamine and asparagine.